mavacamten
Orphan DrugFDA Approved
Description
Mavacamten is a first-in-class cardiac myosin inhibitor that reduces cardiac contractility by decreasing the number of myosin-actin cross-bridges during each cardiac cycle. It is specifically indicated for the treatment of adults with symptomatic New York Heart Association class II-III obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. The drug received FDA approval in April 2022 and orphan drug designation for hypertrophic cardiomyopathy.
Indications & Therapeutic Use
obstructive hypertrophic cardiomyopathy
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
mavacamten
| Generic Name | mavacamten |
| Brands | 1 brand available |
| Active Ingredient | mavacamten |
| Drug Class | obstructive hypertrophic cardiomyopathy |
| Manufacturer | Bristol Myers Squibb |
| Dosage Forms | oral capsule, 2.5mg, 5mg, 10mg, 15mg |
| Medical Code | C01EB23 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT03470545 |
| Countries | 9 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations10 Validated Nodes